title: [Clinical and economic assessment of treatment efficacy of uncomplicated duodenal ulcer with different antisecretory agents in hospital].
abstract: A study of 197 patients with uncomplicated duodenal ulcer revealed clinical and pH-metric particular features of the action of pariet (rabeprazole) and six secretolytics: cimetidine, ranitidine, ranisan, quamatel, omez. It was established that the main clinical criteria of treatment efficacy is duration of ulcer cicatrisation and percentage of cicatrized ulcers during 21 days, and additional criteria are duration of disappearance of clinical signs and stage of acid production suppression. Possibilities of applying methods of pharmacoeconomic study were examined: analysis of the treatment cost, cost minimization, and cost-efficacy with the definition of the increase of expense efficacy for drug selection. It was shown that the cost of the antisecretory therapy makes up from 0.45 to 9.14% of inpatient treatment. A cost-efficacy analysis showed that it is most expedient to use pariet.
authors.forename: S A
authors.initials: SA
authors.lastname: Afendulov
authors.forename: V B
authors.initials: VB
authors.lastname: Maksimenko
authors.forename: T I
authors.initials: TI
authors.lastname: Kalinina
authors.forename: V G
authors.initials: VG
authors.lastname: Pestrikov
authors.forename: G Iu
authors.initials: GIu
authors.lastname: Zhuravlev
authors.forename: E N
authors.initials: EN
authors.lastname: Shamardin
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use*; D016527:Drug Costs; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000191:economics*; D004386:Duodenum / Q000378:metabolism; D005260:Female; D017721:Hospital Costs; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents